Published in J Surg Res on January 01, 1975
Gastric devascularization: a useful salvage procedure for massive hemorrhagic gastritis. Ann Surg (1977) 0.86
Indomethacin and the gastric mucosal blood flow changes of sepsis. Ann Surg (1983) 0.82
Ranitidine and oxygen derived free radical scavengers in haemorrhagic shock induced gastric lesions. Gut (1988) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The vexed question of authorship: views of researchers in a British medical faculty. BMJ (1997) 10.22
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med (1997) 3.33
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Public Health Outreach Forum: lessons learned. Bull Med Libr Assoc (2001) 3.00
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Admission to child health surveillance lists: the views of FHSA general managers and general practitioners. BMJ (1991) 2.82
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Injuries associated with hang gliding. JAMA (1975) 2.65
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology (2008) 2.44
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications: a meta-analysis. Obes Rev (2008) 2.39
A nationally representative study of maternal obesity in England, UK: trends in incidence and demographic inequalities in 619 323 births, 1989-2007. Int J Obes (Lond) (2009) 2.38
Heterologous liver perfusion in treatment of hepatic failure. Ann Surg (1965) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Talcum Powder Granuloma: A Frequent and Serious Postoperative Complication. Ann Surg (1947) 2.14
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Evidence for secular trends in children's physical activity behaviour. Br J Sports Med (2005) 2.07
Congenital anomaly surveillance in England--ascertainment deficiencies in the national system. BMJ (2004) 2.06
Register based study of bladder exstrophy-epispadias complex: prevalence, associated anomalies, prenatal diagnosis and survival. J Urol (2011) 2.03
A new venous prosthesis. Surgery (1972) 2.01
Cancer in minority ethnic populations: priorities from epidemiological data. Br J Cancer Suppl (1996) 1.99
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res (2000) 1.99
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
A molecular investigation of true dominance in Huntington's disease. J Med Genet (1999) 1.92
How to select covariates to include in the analysis of a clinical trial. Control Clin Trials (2000) 1.90
Cancer-related fatigue: A critical appraisal. Eur J Cancer (2006) 1.90
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A (2000) 1.88
Trapped antihydrogen. Nature (2010) 1.85
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Moderate drinking and health: report of an international symposium. CMAJ (1994) 1.65
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol (1991) 1.65
Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective audit. Intern Med J (2007) 1.63
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Metastatic hypernephroma to the head and neck. AJNR Am J Neuroradiol (1988) 1.60
Multiple organ failure. Surg Gynecol Obstet (1977) 1.59
The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem (1998) 1.59
Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab (1970) 1.57
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst (1993) 1.56
The benefits of HIV antibody testing of saliva in field research. Can J Public Health (1992) 1.54
Factors Affecting Hepatic Vascular Resistance in the Perfused Liver. Ann Surg (1963) 1.53
An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosom Med (1992) 1.48
Respiratory abnormalities among grain handlers: a clinical, physiologic, and immunologic study. Am Rev Respir Dis (1977) 1.48
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem (2000) 1.47
Is it possible to catch leukaemia from a cat? Lancet (1994) 1.47
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat (2001) 1.46
Cholecystectomy with and without surgical drainage. Am J Surg (1975) 1.44
The value of community mental health nurses based in primary care teams: 'switching the light on in a cellar'. J Psychiatr Ment Health Nurs (2001) 1.39
Predicting the course of Gompertzian growth. Nature (1976) 1.39
Endoscopic versus operative gastrostomy: final results of a prospective randomized trial. Gastrointest Endosc (1990) 1.39
Editorial: Hang gliding. JAMA (1975) 1.38
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. Cancer J Sci Am (2006) 1.38
Autoresonant excitation of antiproton plasmas. Phys Rev Lett (2011) 1.38
The long-term prognosis in farmer's lung. Am Rev Respir Dis (1968) 1.36
Peritoneal atrial shunt for intractable ascites. Arch Surg (1967) 1.33
Resonant quantum transitions in trapped antihydrogen atoms. Nature (2012) 1.32
Congenital anterior abdominal wall defects. Authors' figures for Northern region are underestimates. BMJ (1997) 1.30
A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene (1997) 1.29
Description and first application of a new technique to measure the gravitational mass of antihydrogen. Nat Commun (2013) 1.25
Decision for surgical management of perforation following endoscopic sphincterotomy. Am Surg (1991) 1.25
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia (2000) 1.25
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol (1995) 1.24
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Epidemiologic study of clinical and physiologic parameters in grain handlers of northern United States. Am Rev Respir Dis (1984) 1.24
Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol (1991) 1.23
Unsuspected depressed cardiac output following blunt thoracic or abdominal trauma. Surgery (1971) 1.23
Obesity in pregnancy: a study of the impact of maternal obesity on NHS maternity services. BJOG (2007) 1.22
Formaldehyde vapor in mobile homes: a cross sectional survey of concentrations and irritant effects. Am J Public Health (1984) 1.22
Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest (1997) 1.22
The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology (1990) 1.21
Liver failure in the postoperative patient: the role of sepsis and immunologic deficiency. Surgery (1975) 1.20
Microdialysis perfusion of 5-HT into hypoglossal motor nucleus differentially modulates genioglossus activity across natural sleep-wake states in rats. J Physiol (2001) 1.19